• Title/Summary/Keyword: Therapeutic oncology

Search Result 803, Processing Time 0.036 seconds

Application of Generalized Batho Method to Arbitrary Shape of Heterogeneous Tissues (일반 Batho방법의 부정형 이질조직에의 적용)

  • Chai, Kyu-Young
    • Radiation Oncology Journal
    • /
    • v.5 no.2
    • /
    • pp.165-168
    • /
    • 1987
  • The generalized Bathe method, proposed by Webb and Fox, which is a method of calculation of dose correction factor for the purpose of heterogeneous tissue, is complex even for a few kind of tissues. The method was modified for the purpose of getting a simple method that divide the multilayer of heterogeneous tissues into some groups of adjacent-tissue pairs. This new method could reduce the number of exponential terms and the time for calculating the dose correction factors by manual and computer calculation.

  • PDF

Esthesioneuroblastoma(Olfactory Neuroblastoma) : Report of Six Cases and Review of the Literature (감각신경모세포종: 증례 보고와 문헌 고찰)

  • Shim Byoung-Yong;Park Jin-No;Han Ji-Youn;Hong Young-Sun;Kim Hoon-Kyo;Lee Kyung-Shick;Kim Min-Sik;Cho Seung-Ho;Chung Su-Mi;Lee Youn-Soo;Kang Jin-Hyoung
    • Korean Journal of Head & Neck Oncology
    • /
    • v.16 no.2
    • /
    • pp.228-234
    • /
    • 2000
  • Objectives: Esthesioneuroblastoma is a rare malignant neoplasm that originates from the olfactory sensory cells. This tumor grows from the upper nasal cavity and ethmoid sinus and invades surrounding structures through the cribriform plate into intracranium or orbit in advanced stage. Even though there has been some controversies in determining standard treatment due to rarity of this tumor, the combination treatment of surgery and adjuvant radiation has been recommended for the locally advanced esthesioneuroblastomas. However, the recent clinical experiences of advanced cases showed that combination chemotherapy is highly effective to reduce tumor mass and improve clinical outcomes. Materials and Methods: The authors conducted a retrospective analysis of 6 esthesioneuroblastoma patients who were treated in our hospital from 1986. Results: The age of these patients was between 19 and 86 year-old. Among the 6 cases, 2 were diagnosed at stage B and 4 at stage C, according to Kadish classification. Anti-tumor treatments were performed in 5 patients. One patient refused active treatment and was lost to follow-up. Better survival outcome were observed in 3 patients who were treated with combination chemotherapy alone or combined modality treatment including chemotherapy. Conclusion: Based on our retrospective study, the combined treatment consisting of surgery, radiotherapy, and combination chemotherapy should be used to improve treatment results. And furthermore, innovative clinical approaches such as neoadjuvant chemotherapy, high-dose chemotherapy and autologous peripheral stem cell transplantation, which have been reported to have good therapeutic results, should be considered and applied actively.

  • PDF

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells

  • Park, Kang-Seo;Hong, Yong Sang;Choi, Junyoung;Yoon, Shinkyo;Kang, Jihoon;Kim, Deokhoon;Lee, Kang-Pa;Im, Hyeon-Su;Lee, Chang Hoon;Seo, Seyoung;Kim, Sang-We;Lee, Dae Ho;Park, Sook Ryun
    • BMB Reports
    • /
    • v.51 no.12
    • /
    • pp.660-665
    • /
    • 2018
  • Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers. However, as with other targeted therapies, intrinsic or acquired resistance to HER2 inhibitors presents unresolved therapeutic problems for HER2-positive gastric cancer. The present study describes investigations with AUY922, a heat shock protein 90 (HSP90) inhibitor, in primary lapatinib-resistant (ESO26 and OE33) and lapatinib-sensitive gastric cancer cells (OE19, N87, and SNU-216) harboring HER2 amplification/over-expression. In order to investigate whether AUY922 could overcome intrinsic and acquired resistance to HER2 inhibitors in HER2-positive gastric cancer, we generated lapatinib-resistant gastric cancer cell lines (OE19/LR and N87/LR) by continuous exposure to lapatinib in vitro. We found that activation of HER2 and protein kinase B (AKT) were key factors in inducing intrinsic and acquired lapatinib-resistant gastric cancer cell lines, and that AUY922 effectively suppressed activation of both HER2 and AKT in acquired lapatinib-resistant gastric cancer cell lines. In conclusion, AUY922 showed a synergistic anti-cancer effect with lapatinib and sensitized gastric cancer cells with intrinsic resistance to lapatinib. Dual inhibition of the HSP90 and HER2 signaling pathways could represent a potent therapeutic strategy to treat HER2-positive gastric cancer with intrinsic and acquired resistance to lapatinib.

Property of Dose Distribution in Accordance with Dose Rate Variation in Intensity Modulated Radiation Therapy (세기조절방사선치료에서 선량율 변화에 따른 선량분포 특성)

  • Kang, Min-Kyu;Kim, Sung-Joon;Shin, Hyun-Soo;Kim, Sung-Kyu
    • Progress in Medical Physics
    • /
    • v.21 no.2
    • /
    • pp.218-222
    • /
    • 2010
  • As radiation is irradiated from various directions in intensity modulated radiation therapy (IMRT), longer treatment time than conventional treatment method is taken. In case of the patients who have problem to keep same posture for long time because of pain and injury, reducing treatment time through increased dose rate is a way for effective treatment. This study measured and found out the variation of dose and dose distribution in accordance with dose rate variation. IMRT treatment plan was set up to investigate from 5 directions - $0^{\circ}$, $72^{\circ}$, $144^{\circ}$, $216^{\circ}$, $288^{\circ}$ - using ECLIPSE system (Varian, SomaVision 6.5, USA). To confirm dose and dose rate in accordance with dose rate variation, dose rate was set up as 100, 300, 500 MU/min, and dose and dose distribution were measured using ionization chamber (PTW, TN31014) and film dosimeter (EDR2, Kodak). At this time, film dosimeter was inserted into acrylic phantom, then installed to run parallel with beam's irradiating direction, 21EX-S (Varian, USA) was utilized as linear accelerator for irradiation. The measured film dosimeter was analyzed using VXR-16 (Vidar System Corporation) to confirm dose distribution.

Aberrant Expression of miR-20a and miR-203 in Cervical Cancer

  • Zhao, Shan;Yao, De-Sheng;Chen, Jun-Ying;Ding, Nan
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.14 no.4
    • /
    • pp.2289-2293
    • /
    • 2013
  • MicroRNAs (miRNAs) are small, non-coding RNAs that are critical regulators of various diseases. MicroRNA-20a (miR-20a) and microRNA-203 (miR-203) have previously shown significant alteration in a range of cancers. In this study, the expression levels of miR-20a and miR-203 in 100 cervical cancer tissues were detected by qRT-PCR and compared to patient matched-nontumor cervical tissues. Correlations between expression level and clinicopathologic characteristics of cervical cancer were also analyzed. Finally, we studied the effect of miR-20a and miR-203 on cell proliferation in cervical cancer cell lines by MTT. We found that the expression level of miR-20a (P<0.001) was significantly higher in cervical cancer patients than in healthy controls, while that of miR-203 (P<0.001) was lower. Aberrant expression of miR-20a was correlated with lymph node metastasis (LNM), histological grade and tumor diameter, but down-regulated miR-203 was correlated with LNM only. Furthermore, we found that over-expression of miR-203 decreased cell proliferation, while reduction of miR-20a also prevented tumor progression. Our results support the involvement of miR-20a and miR-203 in cervical tumorigenesis. We propose that miRNAs might be used as therapeutic agents for cervical cancer.

Cytostatic in vitro Effects of DTCM-Glutarimide on Bladder Carcinoma Cells

  • Brassesco, Maria S.;Pezuk, Julia A.;Morales, Andressa G.;De Oliveira, Jaqueline C.;Valera, Elvis T.;Da Silva, Glenda N.;De Oliveira, Harley F.;Scrideli, Carlos A.;Umezawa, Kazuo;Tone, Luiz G.
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.5
    • /
    • pp.1957-1962
    • /
    • 2012
  • Bladder cancer is a common malignancy worldwide. Despite the increased use of cisplatin-based combination therapy, the outcomes for patients with advanced disease remain poor. Recently, altered activation of the PI3K/Akt/mTOR pathway has been associated with reduced patient survival and advanced stage of bladder cancer, making its upstream or downstream components attractive targets for therapeutic intervention. In the present study, we showed that treatment with DTCM-glutaramide, a piperidine that targets PDK1, results in reduced proliferation, diminished cell migration and G1 arrest in 5637 and T24 bladder carcinoma cells. Conversely, no apoptosis, necrosis or autophagy were detected after treatment, suggesting that reduced cell numbers in vitro are a result of diminished proliferation rather than cell death. Furthermore previous exposure to 10 ${\mu}g/ml$ DTCM-glutarimide sensitized both cell lines to ionizing radiation. Although more studies are needed to corroborate our findings, our results indicate that PDK1 may be useful as a therapeutic target to prevent progression and abnormal tissue dissemination of urothelial carcinomas.

Dosimetric Characteristics of the KCCH Neutron Therapy Facility (원자력병원 중성자선치료기의 물리적특성)

  • Yoo Seong Yul;Noh Sung Woo;Chung Hyun Woo;Cho Chul Koo;Koh Kyoung Hwan;Bak Joo Shik;Eenmaa Juri
    • Radiation Oncology Journal
    • /
    • v.6 no.1
    • /
    • pp.85-91
    • /
    • 1988
  • For the physical characterization of neutron beam, dosimetric measurements had been performed to obtain physical data of KCCH cyclotron-produced neutrons for clinical use. The results are presented and compared with the data of other institutions from the literatures. The central axis percent depth dose, build-up curves and open and wedge isodose curve values are intermediate between that of a 4 and 6 MV X-rays. The build-up level of maximum dose was at 1.35cm and entrance dose was approximately $40\%$. Flatness of the beam was $9\%$ at Dmax and less $than{\pm}3\%$ at the depth of $80\%$ isodose line. Penumbra begond the $20\%$ line is wider than corresponding photon beam. The output factors ranged 0.894 for $6\times6cm$ field to 1.187 for $30\times30cm$ field. Gamma contamination of neutron beam was $4.9\%$ at 2 cm depth in $10\times10cm$ field.

  • PDF

Dendritic Cell Based Cancer Immunotherapy: in vivo Study with Mouse Renal Cell Carcinoma Model (수지상세포를 이용한 항암 면역 치료: 생쥐 신장암 모델을 이용한 연구)

  • Lee, Hyunah;Choi, Kwang-Min;Baek, Soyoung;Lee, Hong-Ghi;Jung, Chul-Won
    • IMMUNE NETWORK
    • /
    • v.4 no.1
    • /
    • pp.44-52
    • /
    • 2004
  • Background: As a potent antigen presenting cell and a powerful inducer of antigen specific immunity, dendritic cells (DCs) are being considered as a promising anti-tumor therapeutic module. The expected therapeutic effect of DCs in renal cell carcinoma was tested in the mouse model. Established late-stage tumor therapeutic (E-T) and minimal residual disease (MRD) model was considered in the in vivo experiments. Methods: Syngeneic renal cell carcinoma cells (RENCA) were inoculated either subcutaneously (E-T) or intravenously (MRD) into the Balb/c mouse. Tumor cell lysate pulsed-DCs were injected twice in two weeks. Intraperitoneal DC injection was started 3 week (E-T model) or one day (MRD model) after tumor cell inoculation. Two weeks after the final DC injection, the tumor growth and the systemic immunity were observed. Therapeutic DCs were cultured from the bone marrow myeloid lineage cells with GM-CSF and IL-4 for 7 days and pulsed with RENCA cell lysate for 18 hrs. Results: Compared to the saline treated group, tumor growth (E-T model) or formation (MRD model) was suppressed in pulsed-DC treated group. RENCA specific lymphocyte proliferation was observed in the RENCA tumor-bearing mice treated with pulsed-DCs. Primary cytotoxic T cell activity against RENCA cells was increased in pulsed-DC treated group. Conclusion: The data suggest the possible anti-tumor effect of cultured DCs in established or minimal residual disease/metastasis state of renal cell carcinoma. Systemic tumor specific immunity including cytotoxic T cell activity was modulated also in pulsed-DC treated group.

Change of Body Weight and Hematologic Value with Aging in Hybrid Mice - Preliminary Study - (한국산 잡종쥐의 성장에 따른 체중 및 혈액상의 변화에 대한 연구)

  • Lee Sung Heon;Cho Kil Ho;Shin Sei One;Kim Myung Se
    • Radiation Oncology Journal
    • /
    • v.3 no.2
    • /
    • pp.169-174
    • /
    • 1985
  • The mouse is one of the most popular experimental animal which has wide variation of strains, diet, environment, breeding technique, and diurnal cycle. Total 731 mice (male 372, female 359) were used for the standard data of our laboratory. Proper age for experiment were $30\pm3$days, body weight were $25\pm2gm (male)$, $23\pm1gm$. (female), minimal diurnal variation showed from 9A.M. to 12P.M.

  • PDF

Postoperative Radiotherapy for Sebaceous Carcinoma of the Upper Eyelid (상안검 피지선암의 수술후 방사선 치료 1례)

  • Chung Su-Mi;Choi Byung-Ock;Choi Ihl-Bohing;Shin Kyung-Sub;Byoun Jun-Hee
    • Korean Journal of Head & Neck Oncology
    • /
    • v.11 no.1
    • /
    • pp.36-40
    • /
    • 1995
  • Sebaceous carcinomas of the eyelids are uncommon but lethal tumors. Lesions are usually seen in the elderly, predominantly women. The meibomian glands of the tarsus are the most frequent site of origin. Less commonly, the tumor arises in other sebaceous glands, e.g., the gland of Zeis, eyebrow or caruncle. Regardless of the location, sebaceous malignancies must be considered aggressive neoplasms with a potential for regional and distant metastasis. Diagnosis may be difficult, given the low incidence and inconsistencies in histopathologic classification. Treatment requires wide surgical excision with removal of involved regional lymph nodes and exenteration is reserved for those patients with orbital involvement or diffuse intraepithelial neoplasia. Opinions are divided regarding the use of postoperative irradiation or chemotherapy. Recently we experienced 46-year-old male patient with a 12-month history of painless, firm nodule and conjunctivitis due to sebaceous carcinoma of the left upper eyelid. After surgery, serial sections of the entire conjunctiva and eyelids showed a positive cut margin in medial and lateral border. We report herein this patient that supports irradiation as the postoperative treatment of these tumors in selected patients with a review of literatures.

  • PDF